联合干扰素-α和 5-氟尿嘧啶治疗伴有主门静脉血栓形成的晚期肝细胞癌的长期疗效。
Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis.
机构信息
Department of Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
出版信息
Oncology. 2011;80(1-2):63-9. doi: 10.1159/000328281. Epub 2011 Jun 9.
BACKGROUND/AIM: We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches. This report describes the results of longer follow-up and includes more than twice the number of patients relative to the previous report; it also evaluates the clinical predictor on the response to the combination therapy and long-term survival.
METHODS
The study subjects were 102 patients with advanced HCC and tumor thrombi in the major branches of the portal vein (Vp3 or 4). They were treated with at least 2 courses of IFN-α/5-FU.
RESULTS
No major treatment-related complications were noted. In the 102 patients, 40 (39.2%) showed objective response [11 (10.8%) showed complete response, 29 (28.4%) partial response], 8 (7.9%) showed no response and 54 (52.9%) showed progressive disease.
CONCLUSION
IFN-α/5-FU combination therapy is a promising modality for advanced HCC with tumor thrombi in the major portal branches.
背景/目的：我们之前报道了干扰素（IFN）-α/5-氟尿嘧啶（FU）联合治疗主门静脉分支内肿瘤血栓的晚期肝细胞癌（HCC）的有益效果。本报告描述了更长随访时间的结果，并且相对于之前的报告，患者数量增加了一倍以上；它还评估了对联合治疗反应和长期生存的临床预测因素。
方法
研究对象为 102 例门静脉主干（Vp3 或 4）有肿瘤血栓的晚期 HCC 患者。他们接受了至少 2 个疗程的 IFN-α/5-FU 治疗。
结果
未观察到与治疗相关的严重并发症。在 102 例患者中，40 例（39.2%）有客观反应[11 例（10.8%）完全缓解，29 例（28.4%）部分缓解]，8 例（7.9%）无反应，54 例（52.9%）疾病进展。
结论
IFN-α/5-FU 联合治疗是主门静脉分支内肿瘤血栓的晚期 HCC 的一种有前途的治疗方法。
Zotero 插件